- Home
- ILLR vs ETON Comparison
ILLR vs ETON Comparison
Compare ILLR & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- ETON
- Stock Information
- Founded
- ILLR 2015
- ETON 2017
- Country
- ILLR United States
- ETON United States
- Employees
- ILLR N/A
- ETON N/A
- Industry
- ILLR Investment Managers
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- ILLR Finance
- ETON Health Care
- Exchange
- ILLR Nasdaq
- ETON Nasdaq
- Market Cap
- ILLR N/A
- ETON 428.5M
- IPO Year
- ILLR N/A
- ETON 2018
- Fundamental
- Price
- ILLR $0.71
- ETON $15.68
- Analyst Decision
- ILLR
- ETON Strong Buy
- Analyst Count
- ILLR 0
- ETON 3
- Target Price
- ILLR N/A
- ETON $29.67
- AVG Volume (30 Days)
- ILLR 1.3M
- ETON 632.7K
- Earning Date
- ILLR 08-15-2025
- ETON 08-07-2025
- Dividend Yield
- ILLR N/A
- ETON N/A
- EPS Growth
- ILLR N/A
- ETON N/A
- EPS
- ILLR N/A
- ETON N/A
- Revenue
- ILLR $45,244,000.00
- ETON $48,327,000.00
- Revenue This Year
- ILLR N/A
- ETON $103.21
- Revenue Next Year
- ILLR N/A
- ETON $51.34
- P/E Ratio
- ILLR N/A
- ETON N/A
- Revenue Growth
- ILLR N/A
- ETON 40.88
- 52 Week Low
- ILLR $0.51
- ETON $3.25
- 52 Week High
- ILLR $6.52
- ETON $21.48
- Technical
- Relative Strength Index (RSI)
- ILLR N/A
- ETON 55.57
- Support Level
- ILLR N/A
- ETON $13.78
- Resistance Level
- ILLR N/A
- ETON $14.70
- Average True Range (ATR)
- ILLR 0.00
- ETON 0.82
- MACD
- ILLR 0.00
- ETON 0.30
- Stochastic Oscillator
- ILLR 0.00
- ETON 89.31
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.